Abstract
Two years into the COVID-19 pandemic there is still a need for vaccines to effectively control the spread of novel SARS-CoV-2 variants and associated cases of severe disease. Here we report a messenger RNA vaccine directly encoding for a nanoparticle displaying 60 receptor binding domains (RBDs) of SARS-CoV-2 that acts as a highly effective antigen. A construct encoding the RBD of the Delta variant elicits robust neutralizing antibody response, and also provides protective immunity against the Delta variant in a widely used transgenic mouse model. We ultimately find that the proposed mRNA RBD nanoparticle-based vaccine provides a flexible platform for rapid development and will likely be of great value in combatting current and future SARS-CoV-2 variants of concern.
Keywords: K18-hACE2; SARS-CoV-2; delta variant; mRNA vaccine; nanoparticle; neutralizing antibody; receptor-binding domain.
【저자키워드】 neutralizing antibody, SARS-CoV-2, mRNA vaccine, delta variant, nanoparticle, receptor-binding domain., K18-hACE2, 【초록키워드】 neutralizing antibody, Vaccine, mRNA vaccine, COVID-19 pandemic, SARS-CoV-2 variant, delta variant, hACE2, Receptor binding domain, Antigen, Spread, Receptor-binding domain, protective immunity, RBD, mRNA, nanoparticle, Neutralizing, platform, RNA vaccine, Neutralizing antibody response, K18-hACE2, RBDs, severe disease, Messenger RNA, domain, messenger, effective, Transgenic mouse, robust, flexible, provide, elicit, the RBD, displaying, 【제목키워드】 Delta, RBD, mRNA, encoding, Against, the SARS-CoV-2,